No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CHRS240517C1000
- 1.15
- +0.05+4.55%
15min DelayClose May 15 15:29 ET
1.15High1.15Low
1.15Open1.10Pre Close1 Volume1.06K Open Interest1.00Strike Price115.00Turnover0.00%IV-0.92%PremiumMay 17, 2024Expiry Date1.17Intrinsic Value100Multiplier2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.89Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Coherus BioSciences Is Maintained at Buy by Truist Securities
Coherus BioSciences Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7
Express News | Coherus BioSciences Inc : Truist Securities Cuts Target Price to $7 From $8
Coherus BioSciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
There's been a notable change in appetite for Coherus BioSciences, Inc. (NASDAQ:CHRS) shares in the week since its quarterly report, with the stock down 16% to US$1.90. It looks to have been a d
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12
Comments
$Coherus BioSciences(CHRS.US$
NEWS
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
Coherus BioSciences, Inc. announced a clinical collaboration with the Cancer Research Institute (CRI) to explore a combination of LOQTORZI (toripalimab-tpzi) with ENB-003 for the treatment of ovarian cancer. The iPROC platform study aims to investigate the ...
NEWS
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
Coherus BioSciences, Inc. announced a clinical collaboration with the Cancer Research Institute (CRI) to explore a combination of LOQTORZI (toripalimab-tpzi) with ENB-003 for the treatment of ovarian cancer. The iPROC platform study aims to investigate the ...
$Coherus BioSciences(CHRS.US$ Press Release: Coherus Amends Term Loan Agreement With Pharmakon Advisors, LP
Dow Jones· 5 mins ago![]()
Dow Jones· 5 mins ago
Analysts' outlook on Coherus BioSciences turns pessimistic with a significant cut to revenue estimates. Despite predicting faster revenue growth than the market, the drastic downgrade for next year's forecasts raises concerns about future performance.
$Coherus BioSciences(CHRS.US$ you want to fly?
$Coherus BioSciences(CHRS.US$ buy and hold
Read more